These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 37932288)
1. Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals. Kreer C; Lupo C; Ercanoglu MS; Gieselmann L; Spisak N; Grossbach J; Schlotz M; Schommers P; Gruell H; Dold L; Beyer A; Nourmohammad A; Mora T; Walczak AM; Klein F Nat Commun; 2023 Nov; 14(1):7137. PubMed ID: 37932288 [TBL] [Abstract][Full Text] [Related]
2. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. Williams WB; Wiehe K; Saunders KO; Haynes BF J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25831. PubMed ID: 34806332 [TBL] [Abstract][Full Text] [Related]
3. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996 [TBL] [Abstract][Full Text] [Related]
4. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses. Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339 [TBL] [Abstract][Full Text] [Related]
5. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781 [TBL] [Abstract][Full Text] [Related]
6. Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals. Martin F; Marcelino JM; Palladino C; Bártolo I; Tracana S; Moranguinho I; Gonçalves P; Mateus R; Calado R; Borrego P; Leitner T; Clemente S; Taveira N Microbiol Spectr; 2022 Dec; 10(6):e0163422. PubMed ID: 36445130 [TBL] [Abstract][Full Text] [Related]
7. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Verkoczy L; Alt FW; Tian M Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799 [TBL] [Abstract][Full Text] [Related]
8. Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses. Tu JJ; Kumar A; Giorgi EE; Eudailey J; LaBranche CC; Martinez DR; Fouda GG; Moreau Y; Thomas A; Montefiori D; Gao F; Sagar M; Permar SR J Virol; 2022 Jun; 96(11):e0023122. PubMed ID: 35536018 [TBL] [Abstract][Full Text] [Related]
9. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423 [TBL] [Abstract][Full Text] [Related]
10. Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. Jardine JG; Sok D; Julien JP; Briney B; Sarkar A; Liang CH; Scherer EA; Henry Dunand CJ; Adachi Y; Diwanji D; Hsueh J; Jones M; Kalyuzhniy O; Kubitz M; Spencer S; Pauthner M; Saye-Francisco KL; Sesterhenn F; Wilson PC; Galloway DM; Stanfield RL; Wilson IA; Burton DR; Schief WR PLoS Pathog; 2016 Aug; 12(8):e1005815. PubMed ID: 27560183 [TBL] [Abstract][Full Text] [Related]
11. Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. Roskin KM; Jackson KJL; Lee JY; Hoh RA; Joshi SA; Hwang KK; Bonsignori M; Pedroza-Pacheco I; Liao HX; Moody MA; Fire AZ; Borrow P; Haynes BF; Boyd SD Nat Immunol; 2020 Feb; 21(2):199-209. PubMed ID: 31959979 [TBL] [Abstract][Full Text] [Related]
12. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage. Sacks D; Wiehe K; Morris L; Moore PL J Virol; 2022 May; 96(10):e0027022. PubMed ID: 35510865 [TBL] [Abstract][Full Text] [Related]
14. Broadly neutralizing antibodies for HIV treatment and cure approaches. Frattari GS; Caskey M; Søgaard OS Curr Opin HIV AIDS; 2023 Jul; 18(4):157-163. PubMed ID: 37144579 [TBL] [Abstract][Full Text] [Related]
20. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? Subbaraman H; Schanz M; Trkola A Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]